ELOVL2

ELOVL2 rs953413 — The Enhancer Switch for DHA Synthesis

The conversion of dietary plant omega-3s into DHA — the brain's dominant structural fat
— is governed by a chain of enzymes whose efficiency varies widely between individuals.
ELOVL2 (elongase of very long chain fatty acids protein 2) catalyzes the critical
elongation step that converts EPA (20:5) into DPA (22:5) and then toward DHA (22:6).
The rs953413 variant, sitting in the first intron of ELOVL2, controls how much of
this enzyme the liver makes. Unlike many GWAS variants whose functional mechanism
remains unknown, rs953413 has a precisely characterized molecular role: it sits inside
a cooperative enhancer element | A regulatory DNA sequence that increases transcription
of a nearby gene when transcription factors bind to it that is bound by the liver
transcription factors
FOXA1/FOXA2 and HNF4α | Hepatocyte nuclear factors — master regulators of liver gene
expression that coordinate fatty acid, glucose, and bile acid metabolism.

The Mechanism

Pan and colleagues | Pan G et al. rs953413 Regulates Polyunsaturated Fatty Acid
Metabolism by Modulating ELOVL2 Expression. iScience, 2020
used luciferase reporter assays, ChIP-qPCR, and CRISPR/Cas9 editing in hepatic cell
lines to show that the G allele of rs953413 preferentially recruits FOXA1, FOXA2,
and HNF4α to an evolutionarily conserved intronic enhancer. This allele-specific
transcription factor binding upregulates ELOVL2 expression. The A allele disrupts
this binding, reducing ELOVL2 transcription. FOXA knockdown and direct Cas9 mutation
of the enhancer both significantly downregulated ELOVL2 expression (p < 0.01),
confirming the causal chain from SNP → transcription factor binding → ELOVL2
expression → LC-PUFA levels.

The downstream consequence is that A-allele carriers produce less ELOVL2 enzyme,
slowing the EPA→DPA→DHA elongation cascade in the liver. This creates a phenotype
with characteristically lower baseline DHA but paradoxically greater responsiveness
to preformed omega-3 supplementation — a pattern seen across multiple independent
intervention trials.

The Evidence

rs953413 was the lead variant in the original
InCHIANTI GWAS | Tanaka T et al. Genome-wide association study of plasma
polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009
of 1,075 Italian adults, where it reached p = 1.1×10⁻⁶ for plasma EPA — establishing
ELOVL2 as a major genetic determinant of omega-3 fatty acid levels in humans. The
signal replicated in 1,076 GOLDN study participants, where ELOVL2 variants were
associated with DPA and DHA levels.

The most striking clinical data comes from an exploratory supplementation trial by
Metherel and colleagues | Metherel AH et al. Higher Increase in Plasma DHA in Females
Compared to Males Following EPA Supplementation May Be Influenced by a Polymorphism
in ELOVL2: An Exploratory Study. Lipids, 2021.
Young adults (n = 14–15 per group) received 3 g/day EPA for 12 weeks. Overall, females
showed substantially greater plasma DHA increases than males (+23.8 vs. −13.8 nmol/mL;
p < 0.01). When stratified by rs953413 genotype, the effect was dramatic: AA-genotype
females gained +58.8 ± 11.5 nmol/mL DHA, compared to +4.34 ± 13.5 nmol/mL for
GA+GG females and −29.1 ± 17.2 nmol/mL for AA males (p < 0.001). This sex × genotype
interaction suggests that estrogen-mediated upregulation of the EPA→DHA elongation
pathway partially compensates for the low-ELOVL2 A-allele phenotype in females,
while AA-genotype males face the full deficit.

The
Alsaleh 2014 fish oil trial | Alsaleh A et al. ELOVL2 gene polymorphisms are associated
with increases in plasma EPA and DHA proportions after fish oil supplement. Genes Nutr,
2014
of 367 subjects confirmed that ELOVL2 minor-allele carriers — across rs953413, rs2236212,
and rs3734398 — showed approximately 30% higher plasma EPA and 9% higher DHA after
1.8 g/day fish oil supplementation (p = 0.002–0.017), reinforcing that preformed omega-3
supply strongly compensates for reduced endogenous elongation.

A notable additional dimension of this locus is its role in
epigenetic aging | DNA methylation changes that accumulate with age and can be used to
predict biological age independently of chronological age.
Garagnani and colleagues | Garagnani P et al. Methylation of ELOVL2 gene as a new
epigenetic marker of age. Aging Cell, 2012
demonstrated that CpG island methylation in the ELOVL2 promoter/enhancer region
correlates with chronological age at r = 0.92 across 501 subjects aged 9–99 years.
The rs953413 variant sits within precisely this regulatory region. Whether the SNP's
effect on transcription factor binding modulates the rate of age-associated methylation
accumulation remains an open research question, but the overlap establishes this locus
as a convergence point for fatty acid metabolism and biological aging biology.

Practical Implications

For AA-genotype individuals, the key implications are: (1) endogenous DHA synthesis
from plant-derived ALA or EPA is constrained by reduced ELOVL2 activity; (2) preformed
DHA supplementation bypasses this bottleneck and is well-supported by multiple
intervention studies; (3) males with AA are at greater deficit than females because
estrogen-mediated elongation partially compensates in women. Fish oil or algae-based
DHA at 1–2 g/day is the most direct intervention, with the omega-3 index as the
objective measure of adequacy.

Interactions

rs953413 is in partial linkage disequilibrium with rs2236212 in European populations,
and both variants affect ELOVL2 activity through different mechanisms: rs2236212 is
associated with reduced enzymatic elongation activity (Maguolo et al. 2021), while
rs953413 acts upstream by controlling transcription factor binding and ELOVL2 gene
expression. Carrying risk alleles at both loci may compound the reduction in DHA
synthesis capacity. Upstream in the same pathway, FADS1/FADS2 variants (rs174547,
rs174537) affect the desaturation of ALA to EPA — individuals with both FADS low-activity
and ELOVL2 low-expression genotypes face impairment at two sequential steps, making
plant-based omega-3 strategies essentially ineffective and preformed marine DHA the
only reliable route to adequate status.